Please select the option that best describes you:
What is the role of targeted therapy in relapsed/refractory ALK+ anaplastic large cell lymphoma?
Would you use ALK inhibitors such as crizotinib based on recent phase II data?
Are there any research efforts to combine ALK inhibitors with current available therapies, such as brentuximab vedotin?
Answer from: at Academic Institution
I recently had an ALCL patient with small cell pathology which, as you know, is a poor prognostic pathology. I asked the same question, and the response from the COG expert, based on the unpublished data from ANHL12P1, was not to add targeted therapy up front but to base the decision on response. I ...
Sign in or Register to read more